CANadian CAnagliflozin REgistry: Effectiveness and safety of canagliflozin in the treatment of type 2 diabetes mellitus in Canadian clinical practice
نویسندگان
چکیده
منابع مشابه
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus
Current guidelines for treatment of type 2 diabetes mellitus (T2DM) indicate a patient-centered approach that should go beyond glycemic control. Of the many antihyperglycemic agents available for treatment of T2DM, sodium-glucose cotransporter 2 (SGLT2) inhibitors offer the advantages of reduced glycated hemoglobin (A1C), body weight (BW), and systolic blood pressure (SBP) and are associated wi...
متن کاملHealth Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Portugal.
◾ CDM calculates indirect costs in relation to fatal events and non-fatal events. The indirect costs associated with productivity loss were included in the base case analyses and were calculated as a function of retirement age, mean salary of males and females (adjusted for employment rates), and average number of working days ◾ For T2DM and its complications, health state utilities for the mod...
متن کاملEfficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
AIMS Patients with type 2 diabetes mellitus (T2DM) have increased risk of adverse events (AEs; e.g. dehydration, hypoglycaemia) in hot weather. This analysis assessed the efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, in patients with T2DM who live in hot climates. METHODS This post hoc analysis evaluated patients with T2DM using pooled data from fo...
متن کاملPharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin in Japanese Patients with Type 2 Diabetes Mellitus
INTRODUCTION Canagliflozin is a sodium glucose co-transporter 2 inhibitor approved worldwide for the treatment of patients with type 2 diabetes mellitus (T2DM). The present study evaluated pharmacokinetics, pharmacodynamics, and safety of canagliflozin in Japanese patients with T2DM. METHODS Canagliflozin, at doses of 25, 100, 200, or 400 mg, was administered as a single dose and, after a was...
متن کاملHealth Economic Evaluation of Canagliflozin in the Treatment of Type 2 Diabetes Mellitus in Czech Republic.
◾ Patient baseline characteristics were taken from the relevant CANA trial in that setting. Treatment effects also came from these trials, with the exception of the comparison to SITA in triple therapy and with DAPA as an add-on to insulin, where treatment effects were taken from the results of a network meta-analysis (NMA; Pacou et al22 and data on file) since direct comparisons were not avail...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Diabetes, Obesity and Metabolism
سال: 2018
ISSN: 1462-8902,1463-1326
DOI: 10.1111/dom.13573